|
CRY1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.00110000026355E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.6993999997832E-07 |
| Normal-vs-Stage2 |
1.013670E-04 |
| Normal-vs-Stage3 |
3.57410000040304E-07 |
| Normal-vs-Stage4 |
1.15199999983773E-07 |
| Stage1-vs-Stage2 |
8.263600E-02 |
| Stage1-vs-Stage3 |
3.790800E-01 |
| Stage1-vs-Stage4 |
1.120380E-01 |
| Stage2-vs-Stage3 |
6.414300E-02 |
| Stage2-vs-Stage4 |
1.785960E-02 |
| Stage3-vs-Stage4 |
5.152800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.79999999963643E-07 |
| Normal-vs-AfricanAmerican |
3.65930000000292E-05 |
| Normal-vs-Asian |
1.91285999999735E-05 |
| Caucasian-vs-AfricanAmerican |
6.164400E-01 |
| Caucasian-vs-Asian |
1.609990E-01 |
| AfricanAmerican-vs-Asian |
6.383200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.55180000025202E-07 |
| Normal-vs-Female |
7.90430000008335E-07 |
| Male-vs-Female |
4.915400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.67359999981143E-07 |
| Normal-vs-Age(41-60Yrs) |
1.49800000004419E-06 |
| Normal-vs-Age(61-80Yrs) |
3.59920000025937E-07 |
| Normal-vs-Age(81-100Yrs) |
4.847700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.959800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.172600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.469800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.941400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.378600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.779800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.013200E-04 |
| Classical-VS-Follicular |
2.081800E-03 |
| Classical-VS-Other |
4.572000E-01 |
| Classical-VS-Normal |
6.12090000018384E-07 |
| Tall-VS-Follicular |
3.6598999997306E-07 |
| Tall-VS-Other |
5.371400E-01 |
| Tall-VS-Normal |
6.75010003448051E-09 |
| Follicular-VS-Other |
1.130380E-01 |
| Follicular-VS-Normal |
2.760900E-04 |
| Other-VS-Normal |
2.37499999999891E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.4107000000374E-06 |
| Normal-vs-N1 |
9.53800000091931E-08 |
| N0-vs-N1 |
6.187800E-02 |
|
|
